pulmonari
surfact
essenti
life
line
alveoli
lower
surfac
tension
therebi
prevent
atelectasi
breath
surfact
enrich
rel
uniqu
phospholipid
term
dipalmitoylphosphatidylcholin
four
surfactantassoci
protein
spa
spb
spc
spd
hydrophob
protein
spb
spc
togeth
dipalmitoylphosphatidylcholin
confer
surfac
tensionlow
properti
materi
hydrophil
surfact
compon
spa
spd
particip
pulmonari
host
defens
modifi
immun
respons
specif
spa
spd
bind
partak
clearanc
varieti
bacteri
fungal
viral
pathogen
dampen
antigeninduc
immun
function
effector
cell
emerg
data
also
show
immunosuppress
action
surfactantassoci
lipid
phosphatidylglycerol
convers
microbi
pathogen
preclin
model
impair
surfact
synthesi
secret
microbi
proteinas
degrad
surfactantassoci
protein
defici
surfact
compon
classic
observ
neonat
respiratori
distress
syndrom
surfact
replac
therapi
mainstay
treatment
howev
function
composit
defici
surfact
also
observ
varieti
acut
chronic
lung
disord
increas
surfact
seen
pulmonari
alveolar
proteinosi
disord
character
function
defici
granulocytemacrophag
colonystimul
factor
receptor
develop
granulocytemacrophag
colonystimul
factor
antibodi
genet
polymorph
surfact
protein
spc
link
interstiti
pulmonari
fibrosi
briefli
review
composit
antimicrobi
properti
relev
pulmonari
surfact
lung
disord
present
therapeut
implic
establish
pulmonari
surfact
reduc
surfac
tension
airwat
interfac
alveoli
therebi
prevent
collaps
structur
endexpir
manner
surfact
reduc
work
associ
breath
although
surfact
surfac
activ
properti
discov
rel
earli
compon
mechan
action
began
elucid
pattl
clement
breakthrough
averi
said
help
identifi
fundament
discoveri
link
pulmonari
surfact
defici
infant
die
respiratori
distress
syndrom
rd
inde
critic
find
help
propel
surfact
replac
therapi
approach
revolution
treatment
rd
howev
investig
uncov
sever
addit
import
biolog
properti
surfaceact
materi
area
host
immun
microbi
infect
immunomodulatori
activ
pulmonari
surfact
compos
primarili
phospholipid
key
protein
lipid
compos
molecular
weight
abund
speci
phosphatidylcholin
phosphatidylglycerol
phosphatidylinositol
figur
specif
phosphatidylcholin
constitut
approxim
lipid
portion
surfact
exist
rel
uniqu
form
known
dipalmitoylphosphatidylcholin
dppc
togeth
surfact
protein
dppc
provid
surfac
activ
surfact
remain
type
lipid
includ
phosphatidylserin
phosphatidylethanolamin
sphingomyelin
appear
present
rel
small
amount
lipid
composit
well
conserv
among
vertebr
surfact
contain
four
associ
protein
surfact
protein
sp
spb
spc
spd
two
protein
spa
spd
hydrophil
other
hydrophob
spa
spd
member
famili
innat
immun
protein
term
collectin
protein
common
nh
termin
collagenlik
region
ctermin
lectin
domain
bind
carbohydr
calciumdepend
manner
bind
site
lectin
domain
found
bacteri
viral
surfac
part
respons
role
collectin
play
innat
adapt
immun
hydrophob
surfact
protein
spb
spc
store
secret
along
surfact
phospholipid
spb
indispens
protein
play
role
enhanc
surfac
tensionreduc
properti
surfact
also
appear
antimicrobi
activ
role
spc
one
hydrophob
peptid
known
uncertain
high
degre
conserv
among
speci
suggest
integr
function
surfact
compon
synthes
primarili
alveolar
type
ii
cell
produc
surfact
lipid
surfact
protein
airway
club
cell
synthes
surfact
protein
spa
spb
spd
figur
main
function
surfact
follow
lower
surfac
tension
airliquid
interfac
thu
prevent
alveolar
collaps
endexpir
interact
subsequ
kill
pathogen
prevent
dissemin
modul
immun
respons
drastic
chang
surfac
area
alveoli
throughout
respiratori
cycl
dictat
alveolar
surfac
tension
need
less
mnm
endexpir
prevent
alveolar
collaps
critic
function
surfact
achiev
mainten
film
highli
enrich
dppc
produc
extrem
low
surfac
tension
mnm
compress
biophys
properti
led
modifi
exogen
surfact
replac
therapi
impact
outcom
neonat
rd
mani
studi
surfact
also
play
vital
role
host
defens
infect
collectin
spa
spd
enhanc
bacteri
viral
clearanc
previous
mention
ctermin
lectin
domain
protein
preferenti
bind
nonhost
oligosaccharid
found
virus
bacteria
welldescrib
function
collectin
abil
opson
pathogen
facilit
phagocytosi
cell
innat
immun
system
macrophag
monocyt
well
regul
product
cellderiv
mediat
studi
shown
mice
defici
spa
exhibit
impair
clearanc
variou
bacteri
viral
infect
includ
group
b
streptococcu
pseudomona
aeruginosa
respiratori
syncyti
viru
recent
spa
spd
also
demonstr
direct
antibacteri
activ
escherichia
coli
klebsiella
pneumonia
enterobact
aerogen
well
antifung
activ
histoplasma
capsulatum
increas
membran
permeabl
microb
human
exist
two
gene
encod
protein
respect
suggest
possibl
may
human
subpopul
differenti
vulner
microbi
infect
base
spa
isoform
addit
facilit
activ
immun
system
lung
collectin
also
act
immunomodul
spa
inhibit
dendrit
cell
matur
inhibit
eosinophil
releas
studi
shown
spa
spd
inhibit
allergeninduc
lymphocyt
prolifer
via
figur
surfact
life
cyclesynthesi
secret
recycl
alveolar
type
ii
cell
cover
alveolar
epitheli
surfac
mainli
respons
surfact
product
use
dietari
substrat
surfact
synthes
endoplasm
reticulum
er
alveolar
type
ii
cell
transport
golgi
modif
surfact
compon
store
lamellar
bodi
secret
liquid
hypophas
alveoli
exocytosi
surfact
form
latticelik
structur
call
tubular
myelin
transport
airliquid
interfac
form
monolay
surfact
film
phospholipid
either
intern
degrad
macrophag
recycl
back
type
ii
cell
reus
note
surfact
protein
sp
spb
spd
also
synthes
club
cell
termin
bronchiol
multipl
mechan
effect
blunt
activ
lymphocyt
children
asthma
spa
spd
also
bind
directli
allergen
particl
pollen
grain
hous
dust
mite
allergen
aspergillu
fumigatu
allergen
inhibit
specif
ige
bind
allergen
subsequ
decreas
allergeninduc
histamin
releas
abnorm
surfact
product
function
associ
sever
pulmonari
diseas
time
pulmonari
infect
alter
surfact
metabol
wellknown
disord
surfact
defici
rd
preterm
infant
discuss
earlier
preterm
neonat
born
produc
enough
surfact
develop
rd
treat
exogen
surfact
sever
genet
disord
caus
surfact
dysfunct
mode
inherit
either
autosom
domin
involv
gene
encod
spc
thyroid
transcript
factor
autosom
recess
involv
gene
encod
spb
gene
encod
atpbind
cassett
protein
member
neonat
genet
disord
surviv
without
lung
transplant
adult
sever
human
observ
studi
show
subject
acut
respiratori
distress
syndrom
ard
alter
composit
function
surfact
unfortun
exogen
surfact
show
mortal
benefit
random
control
trial
rct
although
disord
mention
relat
inadequ
dysfunct
surfact
overabund
surfact
also
caus
clinic
diseas
pulmonari
alveolar
proteinosi
rare
diseas
caus
gene
mutat
lead
dysfunct
granulocytemacrophag
colonystimul
factor
receptor
develop
granulocytemacrophag
colonystimul
factor
antibodi
result
accumul
surfact
within
alveoli
termin
airway
caus
impair
ga
exchang
vari
level
spa
spd
bronchoalveolar
lavag
differ
pulmonari
disord
summar
tabl
previous
believ
surfact
compon
exist
lung
anim
model
human
observ
studi
shown
howev
surfact
protein
leak
vascular
space
alveolocapillari
membran
injur
importantli
circul
surfact
protein
level
may
clinic
use
one
studi
demonstr
surfact
protein
level
use
indic
lung
injuri
poor
outcom
viral
infect
anoth
show
spa
spd
level
elev
pulmonari
fibrosi
compar
healthi
volunt
genet
polymorph
surfact
protein
known
associ
higher
preval
idiopath
pulmonari
fibrosi
also
reduc
preval
interstiti
lung
diseas
system
sclerosi
addit
sever
studi
also
describ
associ
genet
polymorph
surfact
protein
highaltitud
pulmonari
edema
ard
lung
carcinoma
bronchopulmonari
dysplasia
rare
missens
mutat
gene
encod
associ
develop
famili
idiopath
pulmonari
fibrosi
lung
cancer
hand
numer
respiratori
infect
shown
modifi
surfact
composit
exampl
p
aeruginosa
inhibit
surfact
biosynthesi
decreas
host
defens
biophys
function
secret
elastas
degrad
surfact
protein
also
lp
major
cell
wall
compon
gramneg
bacteria
inhibit
phospholipid
synthesi
secret
surfact
inhibit
bacteria
seem
associ
host
cell
cytokin
tumor
necrosi
factora
lead
degrad
surfact
biosynthet
enzym
human
adenoviru
disrupt
traffick
surfact
phosphatidylcholin
wherea
fumigatu
downregul
spb
spc
protein
mrna
express
mice
hydrophil
protein
spa
spd
play
major
role
host
defens
inhibit
bacteri
growth
facilit
bacteri
uptak
host
cell
aggreg
opson
pathogen
surfact
protein
bind
gramneg
gramposit
bacteria
spa
andor
spb
interact
lp
deriv
k
pneumonia
e
coli
p
aeruginosa
legionella
pneumophila
consequ
result
agglutin
enhanc
pathogen
uptak
growth
inhibit
surfact
protein
also
bind
peptidoglycan
cell
wall
compon
gramposit
bacteria
deriv
staphylococcu
aureu
streptococcu
pneumonia
well
mycobacterium
avium
mycobacterium
tuberculosi
mycoplasma
pneumonia
enhanc
uptak
phagocyt
inhibit
growth
spa
spd
abl
bind
varieti
fungi
mostli
opportunist
pathogen
facilit
agglutin
phagocytosi
host
cell
anim
studi
demonstr
pulmonari
collectin
spa
spd
increas
permeabl
cell
membran
h
capsulatum
inhibit
growth
directli
also
bind
fumigatu
blastomyc
dermatitidi
coccidioid
posadasii
cryptococcu
neoforman
pneumocysti
jiroveci
carinii
result
agglutin
enhanc
uptak
interestingli
effect
appear
microb
specif
bind
pulmonari
collectin
candida
albican
inhibit
phagocytosi
alveolar
macrophag
still
inhibit
fungal
growth
pulmonari
collectin
spa
spd
bind
virus
facilit
pathogen
remov
virus
uniqu
compar
mani
microorgan
requir
entranc
host
cell
replic
spa
spd
present
mucu
layer
alveolar
surfac
well
posit
prevent
infect
epitheli
cell
viral
neutral
agglutin
enhanc
phagocytosi
spa
andor
spd
bind
hemagglutinin
neuraminidas
influenza
viru
inhibit
activ
interestingli
hemagglutinin
pandem
influenza
virus
low
bind
activ
surfact
protein
compar
season
influenza
strain
pulmonari
collectin
also
bind
glycoprotein
virus
includ
hiv
rsv
sever
acut
respiratori
syndrom
coronaviru
recent
studi
indic
addit
pulmonari
collectin
surfact
lipid
compon
also
inhibit
rsv
infect
primari
indic
surfact
replac
therapi
rd
preterm
infant
sever
human
observ
studi
rct
demonstr
reduc
mortal
morbid
includ
interstiti
emphysema
pneumothorax
exogen
surfact
administ
preterm
infant
born
less
week
gestat
high
risk
rd
synthet
natur
type
surfact
effect
natur
prepar
retain
surfact
protein
b
c
analog
shown
superior
term
decreas
mortal
lower
rate
rd
complic
preterm
infant
current
american
academi
pediatr
guidelin
recommend
initi
nasal
continu
posit
airway
pressur
immedi
birth
preterm
infant
subsequ
intub
prophylact
earli
surfact
administr
select
patient
endotrach
instil
remain
wide
accept
techniqu
surfact
administr
howev
techniqu
may
complic
episod
sever
airway
obstruct
noninvas
lessinvas
techniqu
includ
aerosol
surfact
laryng
mask
airwayaid
deliveri
pharyng
instil
use
thin
intratrach
cathet
evalu
adult
patient
synthet
natur
anim
surfact
tri
treatment
ard
via
either
intratrach
instil
aerosol
deliveri
howev
studi
demonstr
signific
mortal
benefit
consist
improv
oxygen
approach
initi
believ
exogen
surfact
could
benefici
patient
ard
decreas
surfact
level
persist
atelectasi
contribut
ga
exchang
abnorm
patient
ard
also
alter
composit
function
surfact
compound
mechan
ventil
despit
theoret
sound
exogen
surfact
administr
patient
ard
therapeut
option
limit
justif
time
given
fact
neonat
start
surfact
therapi
earli
cours
diseas
rd
becom
sever
may
worthwhil
consid
studi
approach
earli
surfact
administr
depend
develop
effect
biomark
identifi
predict
patient
ard
earli
cours
diseas
contrari
rd
ard
heterogen
syndrom
variou
degre
inflamm
tissu
remodel
depend
individu
patient
may
explain
differenti
respons
surfact
therapi
altern
util
novel
proteolyt
stabl
surfact
prepar
replac
therapi
might
area
futur
studi
exogen
surfact
also
examin
varieti
lung
diseas
asthma
pneumonia
although
pilot
studi
aerosol
natur
surfact
show
improv
lung
function
acut
asthma
exacerb
show
clinic
benefit
patient
stabl
asthma
one
case
report
demonstr
oxygen
improv
intrabronchi
instil
surfact
adult
patient
gramneg
lobar
pneumonia
case
report
demonstr
similar
oxygen
improv
hivinfect
infant
p
carinii
pneumonia
rsv
pneumonia
one
rct
treatment
cours
aerosol
synthet
surfact
show
improv
pulmonari
function
adult
patient
stabl
chronic
bronchiti
observ
need
confirm
larger
wellcontrol
studi
subject
respiratori
ill
one
potenti
therapeut
implic
surfact
replac
therapi
immunosuppress
anim
studi
limit
human
data
show
exogen
surfact
decreas
cytokin
releas
dna
synthesi
inflammatori
mediat
lymphocyt
prolifer
immunoglobulin
product
express
adhes
molecul
intratrach
administr
surfactantamikacin
mixtur
rat
pseudomona
pneumonia
show
improv
antiinflammatori
effect
compar
amikacin
alon
observ
suggest
possibl
surfact
may
use
modul
immun
respons
inflammatori
lung
diseas
studi
necessari
outsid
exogen
surfact
therapi
also
evid
certain
pharmacolog
agent
may
enhanc
endogen
surfact
level
although
current
data
limit
corticosteroid
wide
use
women
risk
preterm
deliveri
reduc
neonat
morbid
mortal
rd
antenat
steroid
acceler
develop
type
pneumocyt
thu
increas
product
surfact
protein
enzym
necessari
phospholipid
synthesi
corticosteroid
also
induc
pulmonari
breceptor
play
role
surfact
releas
alveolar
fluid
absorpt
stimul
thyroid
hormon
also
synergist
effect
phospholipid
synthesi
corticosteroid
anim
model
ambroxol
may
also
act
increas
surfact
releas
investig
use
rd
hydroxychloroquin
focus
review
anecdot
report
success
treat
children
spc
defici
without
corticosteroid
use
mechan
action
unclear
may
relat
hydroxychloroquin
inhibit
intracellular
process
spc
precursor
lead
late
accumul
spc
agent
keratinocyt
growth
factor
shown
increas
surfact
secret
synthesi
summari
pulmonari
surfact
import
function
beyond
reduc
surfac
tension
alter
mechan
properti
lead
decreas
work
breath
lung
epithelium
constant
exposur
environ
surfact
provid
crucial
first
line
defens
infect
enhanc
remov
pathogen
modul
respons
inflammatori
cell
optim
lung
biophys
activ
hydrophil
protein
constitut
small
portion
surfact
play
major
role
antimicrobi
activ
although
surfact
establish
treatment
rd
preterm
infant
compel
clinic
benefit
use
exogen
surfact
adult
patient
ard
thu
far
studi
need
perform
explor
possibl
surfact
immun
modul
therapi
design
small
molecul
modul
avail
surfact
compon
respiratori
ill
summari
surfact
mani
biolog
function
includ
tensionreduc
properti
airwat
interfac
antimicrobi
activ
immunomodul
although
surfact
establish
treatment
rd
preterm
infant
clinic
benefit
shown
adult
patient
ard
anim
studi
limit
anecdot
report
suggest
surfact
could
use
treat
infecti
inflammatori
lung
diseas
howev
preclin
clinic
studi
necessari
n
author
disclosur
avail
text
articl
wwwatsjournalsorg
